Taiwan Donates Over 51 Million Masks to Countries Worldwide
22.7.2020 12:53:00 EEST | Business Wire | Press release
As the COVID-19 pandemic ravages all parts of the world, Taiwan is lauded for donating over 51 million masks to more than 80 countries working to protect their people and especially front-line medical personnel from the virus.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200722005405/en/
Vice Foreign Minister Miguel Li-jey Tsao (right) shook hands with Robert Seraki Matsebe, head of South Africa’s liaison office in Taipei on May 26, when 50,000 surgical masks were donated to the African republic. The masks would be distributed to doctors and nurses treating patients infected with the COVID-19 virus. (Photo: CNA Photo, courtesy of the Ministry of Foreign Affairs)
As of the end of June, recipients included the United States, Japan, Taiwan’s diplomatic allies, European Union members, other countries in Europe and nations in Southeast Asia and Latin America.
The donations were made in four rounds that began in April, when 10 million masks went to medical workers in the United States and 11 countries in Europe. In the third round, in which over seven million masks were donated in May, 600,000 went to Africa and the Middle East, including aid workers who have been caring for Syrian refugees.
Taiwan is able to help other countries because its government and people have worked together to contain the virus despite its close proximity to China, where the first COVID-19 cases were reported. As of July 21, Taiwan had reported 455 confirmed cases, including 364 imported ones. Only seven of those infected had died.
The island nation has increased its daily production of masks from 1.8 million in January to 20 million by the end of May by putting together a “national team” of machine tool manufacturers and mask makers.
When visiting a member company on the team, President Tsai Ing-wen said that reaching the goal of 20 million masks a day would help boost the morale of the country and prove that Taiwan could push the limits again and again.
There were no strings attached to the international aid, according to Joanne Ou, a spokeswoman for Taiwan’s Ministry of Foreign Affairs (MOFA).
“What Taiwan has done is merely give others a hand when it can manage to look after itself,” Ou told reporters on June 30. “What we’re doing is to fulfill our obligation as a country in the international community and we don’t seek reward or even expect public expressions of gratitude”
Thank-you messages have nonetheless come from all over the world. When Taiwan announced the first round of donations on April 1, American Institute in Taiwan Director William Brent Christensen, the de facto U.S. ambassador, expressed appreciation and called Taiwan “a real friend indeed.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005405/en/
Contact information
Central News Agency
Name: 陳正杰 Jay Chen
Email: jenjey.chen@cna.com.tw
Phone: +886-2-25051180 ext. 100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
